Rep. Julia Letlow, who represents Louisiana in the U.S. House of Representatives, disclosed a purchase of Bristol-Myers Squibb Company Common Stock (BMY) in a Periodic Transaction Report filed under the STOCK Act. The report lists the transaction as a purchase made by Letlow herself, with a value falling between $1,001 and $15,000.
According to the filing, the trade was executed on October 23, 2024, and held through a Merrill Lynch Investment Account identified as #025. The STOCK Act requires members of Congress to publicly disclose covered securities transactions within 45 days of the trade date. In this case, the report was filed 292 days after the October 23, 2024 transaction date, well beyond that 45-day window. The filing itself does not offer an explanation for the delay, and none is speculated here.
What the Filing Shows
The disclosure identifies BMY as the asset involved and classifies the transaction simply as a purchase. Under whoisbuyingnow.com’s internal tagging system, this filing is categorized as a ‘congress buy’ signal, reflecting that a sitting member of the House added shares of the company to a disclosed brokerage account. No additional detail on the rationale behind the purchase, or on any other holdings in the same account, is included in the public report.
Bristol-Myers Squibb is a large pharmaceutical company whose shares are also closely watched by institutional fund managers who file their own quarterly disclosures. Readers interested in how large institutional investors have positioned themselves around healthcare and biotech names can compare notes with our tracking of Capital World Investors’ 13F portfolio moves, which are updated each quarter based on separate SEC filings.
Why the Reporting Window Matters
The STOCK Act’s 45-day disclosure requirement exists to give the public timely visibility into stock transactions made by federal lawmakers, who often have access to information relevant to markets and industries before the general public does. A filing made 292 days after the underlying trade means the public did not have visibility into this specific transaction for nearly ten months after it occurred. This report is being noted here as a matter of public record, not as an allegation of any rule violation or improper conduct.
As with all Periodic Transaction Reports tracked on this site, the underlying filing is a legal disclosure document, and the transaction described is presented here purely as informational reporting on activity that members of Congress are required by law to make public. No inference about the merits of Bristol-Myers Squibb as an investment, or about the reasoning behind Rep. Letlow’s purchase, should be drawn from this reporting.